What Is Axitinib and How Is It Used in Kidney Cancer?

Axitinib (brand name Inlyta) is an oral targeted therapy used to treat advanced renal cell carcinoma (RCC), a common form of kidney cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which block signals that tumors use to grow and make new blood vessels.

Axitinib is often used:

  • As a second-line treatment after the cancer no longer responds to a first treatment
  • In combination with immunotherapy (such as pembrolizumab) as a first-line option for advanced cases

How Does It Work?

Axitinib targets specific proteins called VEGFR-1, VEGFR-2, and VEGFR-3. These proteins play a key role in:

  • Angiogenesis (the formation of new blood vessels)
  • Tumor growth and spread

By blocking these proteins, axitinib helps cut off the tumor’s blood supply, which can slow or stop its growth.

How Is It Taken?

  • Axitinib is taken by mouth, usually twice daily
  • Doses may vary (commonly 5 mg twice daily) and can be adjusted based on tolerance
  • It should be taken at the same time each day, with or without food

Because it is a long-term treatment, patients are monitored regularly with scans and blood tests.

Common Side Effects

Like other TKIs, axitinib can cause:

  • High blood pressure
  • Fatigue
  • Diarrhea
  • Hand-foot syndrome (pain, redness, or peeling skin on hands and feet)
  • Appetite loss
  • Hoarseness
  • Weight loss

Doctors may adjust the dose or add medications to manage side effects.

Is It Effective?

Axitinib has been shown to improve progression-free survival in advanced kidney cancer, especially when used in combination with pembrolizumab. For patients who have failed earlier treatments, it remains a strong option to help control the disease.

Looking for more questions?

Visit our Kidney Cancer Questions page for all other topics explained in plain language.

Comments

Popular posts from this blog

What is Sarcomatoid Kidney Cancer?